Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma

2018 ◽  
Vol 57 (11) ◽  
pp. 1375-1381 ◽  
Author(s):  
Yolanda Delgado Jiménez ◽  
Celia Camarero-Mulas ◽  
Onofre Sanmartín-Jiménez ◽  
Joan R. Garcés ◽  
Manuel Ã. Rodríguez-Prieto ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Basal Cell ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery

scholarly journals Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOSH, Spanish Registry of Mohs Surgery)

2021 ◽  
Author(s):  
Alejandra Tomás-Velázquez ◽  
Onofre Sanmartin-Jiménez ◽  
JR Garcés ◽  
MA Rodríguez-Prieto ◽  
V Ruiz-Salas ◽  
...  
Keyword(s):  
Risk Factors ◽  
Squamous Cell Carcinoma ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Basal Cell ◽  
Squamous Cell Carcinomas ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery

Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of prospective cohorts. This study presents the “real-life” results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1–1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3–6.1), being constant over time (0–5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.

Sign in / Sign up

Export Citation Format

Share Document